Answers are grounded in this paper and cite their sources.
Posterior capsule opacification (PCO) is the most frequent complication of cataract surgery and is driven by the epithelial‐mesenchymal transition (EMT) of residual lens epithelial cells (LECs). The current standard of care, Nd:YAG laser capsulotomy, is reactive and carries well‐documented complications, underscoring the need for proactive pharmacological prophylaxis. Drug‐eluting intraocular lenses offer a localized delivery platform. Here, we developed a sulforaphane (SFN)‐eluting intraocular lens (GelMA‐SFN@IOL) by integrating SFN‐loaded gelatin methacryloyl (GelMA) microparticles onto the IOL haptics. The GelMA carrier was designed to respond to MMP‐2/9, which were upregulated in PCO‐associated capsular tissues. In vitro, MMP‐2 enhanced SFN release from GelMA‐SFN microparticles, supporting enzyme‐responsive release behavior. In TNFα‐stimulated HLE‐B3 cells, SFN suppressed LEC migration and EMT marker expression, accompanied by increased autophagic activity and reduced MMP‐2/9 expression. These findings suggest a potential feedback mechanism whereby SFN‐mediated MMP downregulation could reduce enzyme‐promoted carrier degradation and release as the pathological signal subsides. In a rabbit PCO model, GelMA‐SFN@IOL preserved capsular clarity and reduced aberrant LEC proliferation over 28 days, with no obvious histological abnormalities in the examined ocular tissues. Together, these results support a proof‐of‐concept strategy combining an enzyme‐responsive carrier with an MMP‐modulating therapeutic for early post‐surgical PCO prevention, with potential for self‐limiting release.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: